Wacker, XL-protein sign cooperation agreement to produce biopharmaceuticals

Wacker says that its Wacker Biotech (Jena, Germany) subsidiary and XL-protein (Freising, Germany), a privately owned biopharmaceutical company, have signed an agreement to collaborate more intensely on the production of PASylated therapeutic proteins. Through this collaboration, Wacker and its customers will gain access to XL-protein’s PASylation platform. The PASylation technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly, Wacker says. In a recent...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers